Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
IPO Year: 2004
Exchange: NASDAQ
Website: dynavax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $15.00 → $12.00 | Neutral → Sell | Goldman |
| 2/1/2024 | $20.00 | Neutral | Goldman |
| 9/27/2022 | $22.00 | Mkt Outperform | JMP Securities |
| 1/6/2022 | $38.00 | Buy | Goldman |
| 12/29/2021 | $23.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/31/2021 | $20.00 → $23.00 | Buy | HC Wainwright & Co. |
| 8/6/2021 | $19.00 | Buy | Goldman Sachs |
| 8/5/2021 | $16.00 → $20.00 | Buy | HC Wainwright & Co. |
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13D - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
DEFC14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
DEFC14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
PRER14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
PREC14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
DFAN14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
144 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatitis B virusFindings released during Hepatitis Awareness Month underscore the importance of public education to address misunderstandings about hepatitis B and raise awareness of the Centers for Disease Control and Prevention (CDC) universal recommendation that eligible adults over 19 receive the hepatitis B vaccineResults will be discussed with a panel of hepatitis B experts during the May 27th LinkedIn Live eventEMERYVILLE, Calif., May 1, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NAS
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif., April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today mailed a letter to its stockholders in connection with its 2025 Annual Meeting of Stockholders ("Annual Meeting") urging stockholders to vote the GOLD proxy card "FOR" all four of Dynavax's highly qualified directors standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun. The Annual Meeting will be held on June 11,
EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav
Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif., April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockhol
Believes Company's Unwillingness to Reach Mutually Acceptable Resolution – And Opposition to Giving Shareholders a Voice in the Boardroom – Underscores the Board's Entrenchment and the Clear Need for Investor-Driven Change Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we") is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.34% of the Company's outstanding shares. Today Deep Track commented on the Company's disclosure that the Board of Directors (the "Board") has rejected a settlement proposal in connection with its nomination of four highly qualified candidat
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif., April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders ("the 2025 Annual Meeting"). The preliminary proxy statement is available on the investor relations section of the Company's website at https://investor
Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the
Notes Investor Feedback Supporting Deep Track's Course of Action and Sharing Concerns with Company's Capital Allocation Strategy, Poor Governance, and Lack of Shareholder Perspective in the Boardroom Highlights Dynavax's Refusal to Reach a Constructive Resolution and Calls on Board to Stop Engaging in Petty "Activism Defense 101" Tactics Questions Company's Issuance of Expensive Convertible Notes in Recent Refinancing Instead of Using Cash on Hand Sets Record Straight Regarding Dynavax's Misleading Assertion That Deep Track is Seeking Control of the Board – Which is Simply False Reiterates Need for a Refreshed Board to Drive Critical Strategic Improvements and Protect the Long-Term Inte
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure$225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new moneyDynavax repurchased ~$8 million of the Company's common stock in connection with this transactionEMERYVILLE, Calif., March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Ex
EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2024.
EMERYVILLE, Calif., Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website
HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growthHepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market shareExpect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24 $200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commerci
EMERYVILLE, Calif., Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan"). The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Track Capital, which recently disclosed in a Schedule 13D/A filing its ownership of 13.6% of the Company's outstanding common stock. The Rig
EMERYVILLE, Calif., Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://inve
Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million, growing 24% year-over-yearReaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 millionInitiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 6, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2024.
EMERYVILLE, Calif., July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors
HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 millionAnnounces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles programConference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif., May 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2024.
EMERYVILLE, Calif., April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, May 8, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.d
Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously
Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00
JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00
Goldman resumed coverage of Dynavax with a rating of Buy and set a new price target of $38.00
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $28.00 from $23.00 previously
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $23.00 from $20.00 previously
Goldman Sachs initiated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $19.00
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $20.00 from $16.00 previously
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $15.00 from $14.00 previously
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif., April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockhol
Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. The Company also confirmed that Deep Track Capital ("Deep Track") has submitted a letter purporting to nominate four candidates to stand for election to the Dynavax Board of Directors at the Company's 2025 Annual Meeting of Stockholders.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h
EMERYVILLE, Calif., Dec. 14, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines to protect the world against infectious diseases, today announced the appointment of Elaine Sun to its Board of Directors. "We are delighted to welcome Elaine to our Board of Directors. Her strategic, operational and financial experience in the life sciences industry will be a strong addition to our current Board," commented Ryan Spencer, Chief Executive Officer of Dynavax. "We look forward to El
EMERYVILLE, Calif., Oct. 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Scott Myers to its Board of Directors. Mr. Myers was also elected Board Chairman, succeeding Dr. Andrew Hack who has served as interim Chairman of the Board since May 2020. Dr. Hack will continue to serve on the Board of Directors. "I am excited to have Scott join the Board of Directors as he brings tremendous depth and breadth of highly relevant experience as
EMERYVILLE, Calif., June 29, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021, the Company granted him a non-statutory stock option to purchase 300,000 shares of Dynavax common stock. The stock option has a 7-year term and vests over three years, with one-third of the shares underlying the option vesting on the one-year anniversary of the grant date, and the remaining shares vesting 1/36 per month in equal installments, subject t
EMERYVILLE, Calif., Jan. 20, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Kelly MacDonald has been appointed Senior Vice President and Chief Financial Officer. Ms. MacDonald will join the company effective March 1, 2021. As previously announced, after 14 years at Dynavax, Chief Financial Officer Michael Ostrach is retiring. Mr. Ostrach has agreed to remain available as an advisor to the Company thereafter. Dynavax Appoints Kelly MacDonald as Chief Financial Officer "Michael's contributions and unwavering commitment to Dynavax have been critic
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi